SABR-COMET-3

• Research type

  Research Study

• Full title

  A phase III randomized controlled trial and economic evaluation of Stereotactic Ablative Radiotherapy (SABR) for Comprehensive treatment of OligoMETastatic (1-3 metastases) cancer.

• IRAS ID

  278062

• Contact name

  Iain Phillips

• Contact email

  iain.phillips@nhslothian.scot.nhs.uk

• Sponsor organisation

  BC Cancer - Prince George

• Clinicaltrials.gov Identifier

  NCT03862911

• Duration of Study in the UK

  6 years, 7 months, 28 days

• Research summary

  The purpose of this study is to determine the utility and cost effectiveness of stereotactic ablative radiotherapy (SABR) for patients with oligometastatic disease. The primary objective is to compare the effect of SABR, relative to standard of care (SOC) alone, on overall survival for patients with 1-3 metastatic lesions. Secondary objectives will compare progression-free survival, toxicity, and quality of life. An integrated economic evaluation will determine the cost per quality of life year gained using SABR (vs. SOC). A further translational component will enable identification of predictive/prognostic biomarkers of the oligometastatic state.

• REC name

  South East Scotland REC 01

• REC reference

  20/SS/0116

• Date of REC Opinion

  29 Jan 2021

• REC opinion

  Further Information Favourable Opinion